Avelumab generic Avelumab is a programmed death ligand-1 (PD-L1) blocking antibody which is prescribed to treat adult and pediatric patients of 12 years and older who suffer from advanced Merkel-cell carcinoma that has spread to other parts of the body. Merkel-cell carcinoma is a rare but highly aggressive form of skin cancer caused by the Merkel cell polyomavirus. Avelumab is also used to treat urothelial cancer (cancer that occurs in the bladder, ureter, and urethra) in patients whose cancer was worsened during chemotherapy or within 12 months of chemotherapy given with surgery. It received orphan drug designation in January 2017 by the European Medicines Agency (EMA) for treating stomach cancer. Avelumab acts either by slowing down the growth of cancer cells or stops the further development of cancer.
More Info about Avelumab